Hill Lisa J, Mead Ben, Thomas Chloe N, Foale Simon, Feinstein Elena, Berry Martin, Blanch Richard J, Ahmed Zubair, Logan Ann
Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom.
Section of Retinal Ganglion Cell Biology, Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, MD.
Mol Vis. 2018 Oct 29;24:712-726. eCollection 2018.
Elevations in intraocular pressure (IOP) are associated with the development of glaucoma and loss of sight. High transforming growth factor-β (TGF-β) 1 levels in the eye's anterior chamber can lead to dysfunctional contractions through RhoA signaling in trabecular meshwork (TM) cells and IOP spikes. Sustained high TGF-β levels leads to TM fibrosis and sustained increases in IOP. We investigated whether inhibiting RhoA, using a siRNA-mediated RhoA (siRhoA), controls IOP by altering TM expression of fibrosis and contractility-related proteins in a rodent model of glaucoma.
TGF-β was injected intracamerally twice a week into adult Sprague Dawley rats, and IOP was recorded with tonometry. Animals were euthanized on day 7 and 35 with TM expression of fibrosis and contractility-related proteins, as well as survival of retinal ganglion cells (RGCs) assessed with immunohistochemistry. siRNA against RhoA or enhanced green fluorescent protein (EGFP) was also injected intracamerally into select animals. Successful RhoA knockdown was determined with quantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry, and the effects of the knockdown on the parameters above analyzed.
TGF-β caused increased TM contractile proteins and IOP spikes by day 7, sustained increases in IOP from day 15, and TM fibrosis at day 35. siRhoA abolished the transient 7 day IOP rise but not the later sustained IOP increase (due to fibrosis). At 35 days, TGF-β-related RGC loss was not prevented with siRhoA treatment.
We conclude that RhoA signaling mediates the early IOP rise induced by TM cellular changes associated with contractility but not the sustained IOP elevation caused by TM fibrosis. Thus, RhoA therapies offer a clinically relevant opportunity for IOP management, likely through the modulation of TM contractility, but appear to be ineffective in the amelioration of fibrosis.
眼压(IOP)升高与青光眼的发生及视力丧失相关。眼前房内高转化生长因子-β(TGF-β)1水平可通过小梁网(TM)细胞中的RhoA信号传导导致功能失调的收缩及眼压峰值。持续的高TGF-β水平会导致TM纤维化及眼压持续升高。我们研究了在青光眼啮齿动物模型中,使用小干扰RNA介导的RhoA(siRhoA)抑制RhoA是否通过改变TM中纤维化和收缩性相关蛋白的表达来控制眼压。
每周两次向成年Sprague Dawley大鼠前房内注射TGF-β,并用眼压计记录眼压。在第7天和第35天对动物实施安乐死,通过免疫组织化学评估TM中纤维化和收缩性相关蛋白的表达以及视网膜神经节细胞(RGCs)的存活情况。还向选定的动物前房内注射针对RhoA或增强型绿色荧光蛋白(EGFP)的小干扰RNA。通过定量逆转录聚合酶链反应(RT-PCR)和免疫组织化学确定RhoA的成功敲低,并分析敲低对上述参数的影响。
到第7天时,TGF-β导致TM收缩蛋白增加和眼压峰值,从第15天起眼压持续升高,在第35天时出现TM纤维化。siRhoA消除了第7天短暂的眼压升高,但未消除后期由于纤维化导致的眼压持续升高。在第35天时,siRhoA治疗未能预防TGF-β相关的RGC丢失。
我们得出结论,RhoA信号传导介导了由与收缩性相关的TM细胞变化引起的早期眼压升高,但不介导由TM纤维化导致的眼压持续升高。因此,RhoA疗法可能通过调节TM收缩性为眼压管理提供了一个临床相关的机会,但在改善纤维化方面似乎无效。